Tuesday, 27 June 2023
Gain valuable insights from Dr. Wagle and ASC Administrator Heather Higendorf-Cooley as they share their comprehensive perspectives on OMIDRIA, spanning clincal expertise and administrative considerations.
OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.
OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.
Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2022 Rayner Group, all rights reserved. US-OM-2200071 12/22